PA5-55591

antibody from Invitrogen Antibodies

Targeting: ALKAL1 AUGB, FAM150A, UNQ9433

Antibody data

Submit

Validation data

Product number: PA5-55591 - Provider product page
Provider: Invitrogen Antibodies
Product name: FAM150A Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Recombinant protein fragment
Description: Immunogen sequence: ARVTDKEPKP LLFLPAAGAG RTPSGSRSAE IFPRDSNLKD KFIKHFTGPV TFSPECSKHF Highest antigen sequence identity to the following orthologs: Mouse - 65%, Rat - 70%.
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 0.1 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

ALKAL1 protein structure - PA5-55591 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 ALKAL1 is upregulated in colorectal cancer tissues and cell lines. A-D) ALKAL1 expression levels was markedly upregulated in colorectal cancer tissues as assessed by analyzing TCGA colorectal cancer miRNA sequencing datasets. (E) Real-time PCR analysis of ALKAL1 in 10 primary colorectal cancer tissues compared with the matched adjacent normal tissues (ANT). (F) ALKAL1 protein expression in 10 paired CRC and adjacent normal tissues (ANT) from the same patient were detected by Western blot. alpha-tubulin was used as the loading control. (G) ALKAL1 mRNA expression was determined by RT-PCR in selected 8 colorectal cancer cell lines (Caco-2, DLD-1, HCT-8, LS 174T, RKO, SW480, SW620 and T84). (H) ALKAL1 protein expression was determined by Western blot in selected 8 colorectal cancer cell lines (Caco-2, DLD-1, HCT-8, LS 174T, RKO, SW480, SW620 and T84).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Upregulation of ALKAL1 correlates with tumor malignancy and poor prognosis in colorectal cancer. (A) Representative photomicrographs of immunohistochemical analysis for ALKAL1 expression at various pathological stages, including benign, precancerous, and tumor stages I to IV. ALKAL1 was stained in brown. (B) Distribution of ALKAL1 immunostaining index across a variety of pathological stages of colorectal cancer. High expression of ALKAL1 was observed in 240/353 colorectal cancer tissue samples. (C-E) High expression of ALKAL1 was strong positive correlated with tumor classification, node classification and pathological stages. (F) Kaplan-Meier survival analysis revealed that patients with high ALKAL1 expression had poor overall survival. (G) Kaplan-Meier analysis of overall survival curves of colorectal cancer patients datasets from TCGA.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 ALKAL1 silencing is not associated with colorectal cancer cell proliferation. (A) Real-time PCR analysis of ALKAL1 expression in ALKAL1 silencing RKO and SW480 cell lines by endogenously knocking down ALKAL1 with retrovirus (sh.#1 and sh.#2) infection. (B) Western blot analysis of ALKAL1 expression in ALKAL1 silencing RKO and SW480 cell lines by endogenously knocking down ALKAL1 with retrovirus (sh.#1 and sh.#2) infection. (C-D) CCK-8 analysis of RKO and SW480 cells proliferation. (E) Plate colony formation analysis of RKO and SW480 cell by endogenously knocking down ALKAL1 with retrovirus (sh.#1 and sh.#2) infection. (F) Cell cycle analysis with PI staining analysis of RKO and SW480 cells by endogenously knocking down ALKAL1 with retrovirus (sh.#1 and sh.#2) infection. Error bars represent the mean +- S.D. of three independent experiments. * P < 0.05.